These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 18474372

  • 1. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
    Stüve O.
    J Neurol Sci; 2008 Nov 15; 274(1-2):39-41. PubMed ID: 18474372
    [Abstract] [Full Text] [Related]

  • 2. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct 15; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 3. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK.
    Ann Neurol; 2006 May 15; 59(5):743-7. PubMed ID: 16634029
    [Abstract] [Full Text] [Related]

  • 4. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
    del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O.
    Arch Neurol; 2008 Dec 15; 65(12):1596-603. PubMed ID: 18852339
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Dec 15; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
    Mareckova H, Havrdova E, Krasulova E, Vankova Z, Koberová M, Sterzl I.
    Ann N Y Acad Sci; 2007 Sep 15; 1110():465-73. PubMed ID: 17911462
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 15; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 8. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2007 Jul 15; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 9. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
    Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R.
    Brain; 2011 Sep 15; 134(Pt 9):2687-702. PubMed ID: 21908874
    [Abstract] [Full Text] [Related]

  • 10. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov 15; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

  • 11. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
    Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.
    Arch Neurol; 2007 Feb 15; 64(2):169-76. PubMed ID: 17296831
    [Abstract] [Full Text] [Related]

  • 12. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
    Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E.
    Eur Neurol; 2010 Feb 15; 63(5):311-7. PubMed ID: 20453514
    [Abstract] [Full Text] [Related]

  • 13. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK.
    Am J Manag Care; 2010 Jun 15; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct 15; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 15. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C.
    N Engl J Med; 2009 Sep 10; 361(11):1081-7. PubMed ID: 19741229
    [Abstract] [Full Text] [Related]

  • 16. A giant MS plaque mimicking PML during natalizumab treatment.
    Twyman C, Berger JR.
    J Neurol Sci; 2010 Apr 15; 291(1-2):110-3. PubMed ID: 20144466
    [Abstract] [Full Text] [Related]

  • 17. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J.
    Am J Manag Care; 2010 Jun 15; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [Abstract] [Full Text] [Related]

  • 18. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 Sep 02; 71(10):766-73. PubMed ID: 18765653
    [Abstract] [Full Text] [Related]

  • 19. Multiple sclerosis and Natalizumab.
    Fiore D.
    Am J Ther; 2007 Sep 02; 14(6):555-60. PubMed ID: 18090880
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul 02; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.